Viva in Vitro Raises 1.3 Million Euros to Develop Treatments Against Sepsis

Viva in Vitro is in full swing in the race to make a name for itself in immunological medicine. The Spanish biotechnology company has raised more than 1.3 million euros in a third consecutive round, which will end in July 2024.

In this way, the company led by Toni Vilaplana has already raised more than 3.2 million euros in funding in less than three years, combining private investment (2.6 million euros) and the support of public administrations (600,000 in subsidies). The priorities are to expand the clinical validation of its solutions and to bring its Viva Sepscare device to market.

One of the investors that has participated in this third round of investment is Murcia Emprende, the venture capital company of the Institute for the Promotion of the Region of Murcia, with the participation of national banking entities.

Select investors and family offices linked to the business ecosystem of Murcia and Alicante have joined this vehicle , including Rafael Crespo, who will become part of its board of directors , as well as Enrique Riquelme and Guillermo Forner, who together with Murcia Emprende will join a newly created advisory board.

They have been joined by investors such as Antonio Ruiz Ballesta, Fran Rodríguez and Antonio Soria. The new board of directors of Viva in Vitro is made up of Joaquín Gómez Moya, Toni Vilaplana and Rafael Crespo.

Viva in Vitro hopes to reduce hospital mortality from sepsis by 25% to 45%

Dr. Pablo Pelegrín, founder of the company and coordinator of the International Scientific Advisory Committee of Viva in Vitro, stated: “We have achieved milestones of global relevance with the degree of development reached in the device for detecting the activation level of these biomarkers on which to base new advances in precision or personalized medicine.”

Viva in Vitro plans to extend its clinical validation to other fields such as multiple sclerosis and other diseases in the near future. Research focused on inflammatory diseases related to Nlrp3 is attracting the interest of corporations with numerous projects focused on this market in the last five years.

Sepsis alone causes more than eleven million deaths each year in the Western world, with more than 55 million people affected. One in five people die, while in the European Union (EU) alone it costs more than 17 billion euros for treatments that last for weeks in hospitals.

Thanks to its Viva Sepscare, Viva in Vitro hopes to contribute to reducing hospital mortality due to this disease by between 25% and 45% , where the key is the prognosis (negative evolution forecast) and the stratification of patients.

__

(Featured image by Myriam Zilles via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us